Form 4: InMed COO's Stock Options Expire

InMed Pharmaceuticals Inc. Chief Operating Officer Michael Woudenberg reported the expiration of 60 employee stock options.

Summary

• Michael Woudenberg, Chief Operating Officer of InMed Pharmaceuticals Inc., reported the expiration of 60 employee stock options.
• The options had an exercise price of $1,397.97 per share, converted from C$1,925.00 using an exchange rate of C$1.3770 = $US1.00.
• These options became exercisable on December 16, 2020, and expired on December 15, 2025.
• Following this expiration, Michael Woudenberg beneficially owns 7,445 derivative securities directly.

Sentiment

Score: 5

Explanation: The filing reports the expiration of employee stock options, a routine event for equity compensation. The $0.00 price of the derivative suggests the options were not exercised, which is neutral to slightly negative for the option holder but does not directly indicate company performance.

Negatives

• The expiration of 60 employee stock options, likely unexercised, indicates that the stock price was below the exercise price of $1,397.97 per share at the time of expiration, resulting in a loss of potential value for the Chief Operating Officer.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: The expiration of these options means there is no additional dilution from these specific options being exercised. However, the implied stock performance (below exercise price) could be a minor concern.
• Employee (Michael Woudenberg): Lost potential value from 60 options that expired unexercised.

Key Dates

Keywords

InMed Pharmaceuticals, INM, Form 4, stock options, insider trading, beneficial ownership, Michael Woudenberg, Chief Operating Officer, equity compensation